◼ Archived
Business
🔮 fades ✓
Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer
Tango reports 82% tumor response rate in advanced pancreatic cancer trial
Daraxonrasib
12 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Daraxonrasib
This hub groups 12 separate news trends connected to Daraxonrasib, spanning June 25, 2026 through October 23, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 99 article observations and 96 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Health
🔮 fades ✓
How a Promising Pancreatic Cancer Drug Loses Its Punch
A Phase 3 trial launches a new drug duo for RAS G12D pancreatic cancer amid low five‑year survival rates.
◼ Archived
Business
🔮 fades ✓
A breakthrough pancreatic cancer drug won approval. They still struggle to access it
FDA approval gives pancreatic cancer patients a new RAS‑targeted drug, but supply hurdles keep many waiting.
◼ Archived
Business
🔮 fades ✓
Newly approved pancreatic cancer drug shows promise in lung cancer
Newly approved pancreatic cancer drug may extend survival for lung cancer patients.
◼ Archived
Business
🔮 fades ✓
FDA approves landmark pancreatic cancer drug that’s shown to improve survival
A new drug has been approved for pancreatic cancer, but it's not clear who will pay for it.
◼ Archived
Business
🔮 fades ✓
F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer
The FDA has approved a new drug for pancreatic cancer, marking a significant milestone in treatment options.
◼ Archived
Health
🔮 fades ✓
Patients receive ‘historic’ pill for deadly pancreatic cancer
Patients with pancreatic cancer are receiving a new pill treatment, marking a significant milestone in cancer therapy.
◼ Archived
Health
🔮 fades ✓
Patients in Illinois starting to receive experimental pancreatic cancer drug: ‘Game changer’
Patients in Illinois and Utah are among the first to receive a new experimental drug for pancreatic cancer.
◼ Archived
Health
🔮 holds ✗
Pancreatic cancer drug now available in Cleveland offers new hope
Medical advancements in pancreatic cancer treatment, specifically involving Daraxonrasib and RASolute-302 data, are expanding patient access in clinical settings.
◼ Archived
Health
🔮 holds ✗
Pancreatic cancer breakthrough has big implications for early detection effort - San Diego Union-Tribune
An experimental pill called daraxonrasib is showing promising early results and gaining regulatory attention for treating pancreatic cancer.
◼ Archived
Business
🔮 fades ✓
Revolution Medicines shares promising data around KRAS drug combination
Revolution Medicines has released promising Phase 1/2 clinical data for a KRAS drug combination targeting metastatic pancreatic cancer.
◼ Archived
Health
🔮 fades ✓
Grand Rapids oncologist says experimental pancreatic cancer drug showing promise in trials offers hope
An experimental drug for pancreatic cancer is generating hope among medical professionals and patients.